Market Closed -
Nasdaq
04:00:00 2024-05-31 pm EDT
|
5-day change
|
1st Jan Change
|
31.88
USD
|
+2.18%
|
|
+2.11%
|
+139.70%
|
Fiscal Period: December |
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Capitalization
1 |
954.3
|
606
|
604.1
|
816.3
|
3,161
|
-
|
-
|
Enterprise Value (EV)
1 |
609
|
229.5
|
348.1
|
693.2
|
2,679
|
2,708
|
2,764
|
P/E ratio
|
-5.08
x
|
-4.06
x
|
-3.59
x
|
-3.37
x
|
-10.5
x
|
-10.4
x
|
-11.5
x
|
Yield
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Capitalization / Revenue
|
-
|
-
|
-
|
-
|
-
|
191
x
|
54.7
x
|
EV / Revenue
|
-
|
-
|
-
|
-
|
-
|
164
x
|
47.8
x
|
EV / EBITDA
|
-10.5
x
|
-1.54
x
|
-2.06
x
|
-2.88
x
|
-9.53
x
|
-9.1
x
|
-9.13
x
|
EV / FCF
|
-12.8
x
|
-1.86
x
|
-2.22
x
|
-3.67
x
|
-11.3
x
|
-11.4
x
|
-12.8
x
|
FCF Yield
|
-7.83%
|
-53.7%
|
-45%
|
-27.2%
|
-8.82%
|
-8.75%
|
-7.82%
|
Price to Book
|
2.79
x
|
1.67
x
|
2.39
x
|
8.7
x
|
3.8
x
|
4.1
x
|
6.09
x
|
Nbr of stocks (in thousands)
|
45,445
|
50,970
|
52,124
|
61,376
|
99,165
|
-
|
-
|
Reference price
2 |
21.00
|
11.89
|
11.59
|
13.30
|
31.88
|
31.88
|
31.88
|
Announcement Date
|
3/4/21
|
3/10/22
|
3/2/23
|
3/5/24
|
-
|
-
|
-
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net sales
1 |
-
|
-
|
-
|
-
|
-
|
-
|
16.54
|
57.8
|
EBITDA
1 |
-
|
-57.95
|
-148.9
|
-169.3
|
-240.5
|
-281.2
|
-297.5
|
-302.7
|
EBIT
1 |
-
|
-58.65
|
-150
|
-171
|
-242.2
|
-272.7
|
-303.5
|
-298.5
|
Operating Margin
|
-
|
-
|
-
|
-
|
-
|
-
|
-1,835.45%
|
-516.49%
|
Earnings before Tax (EBT)
1 |
-
|
-59.44
|
-149.3
|
-168.1
|
-235.9
|
-258.6
|
-318.2
|
-354.3
|
Net income
1 |
-14.86
|
-59.44
|
-149.3
|
-168.1
|
-235.9
|
-257.1
|
-289.5
|
-279.6
|
Net margin
|
-
|
-
|
-
|
-
|
-
|
-
|
-1,750.86%
|
-483.71%
|
EPS
2 |
-1.830
|
-4.130
|
-2.930
|
-3.230
|
-3.950
|
-3.048
|
-3.073
|
-2.779
|
Free Cash Flow
1 |
-
|
-47.67
|
-123.2
|
-156.7
|
-188.9
|
-236.2
|
-236.8
|
-216
|
FCF margin
|
-
|
-
|
-
|
-
|
-
|
-
|
-1,432.07%
|
-373.75%
|
FCF Conversion (EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
FCF Conversion (Net income)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Dividend per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
8/25/20
|
3/4/21
|
3/10/22
|
3/2/23
|
3/5/24
|
-
|
-
|
-
|
Fiscal Period: December |
2021 Q4
|
2022 Q1
|
2022 Q2
|
2022 Q3
|
2022 Q4
|
2023 Q1
|
2023 Q2
|
2023 Q3
|
2023 Q4
|
2024 Q1
|
2024 Q2
|
2024 Q3
|
2024 Q4
|
2025 Q1
|
2025 Q2
|
---|
Net sales
1 |
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
EBITDA
1 |
-51.62
|
-35.36
|
-52.3
|
-41.88
|
-39.74
|
-45.05
|
-66.3
|
-61.84
|
-67.29
|
-
|
-57
|
-60
|
-64
|
-
|
-
|
EBIT
1 |
-51.96
|
-35.78
|
-52.76
|
-42.28
|
-40.15
|
-45.46
|
-66.74
|
-62.27
|
-67.69
|
-69.16
|
-63.02
|
-66.31
|
-69.19
|
-78.17
|
-85.87
|
Operating Margin
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Earnings before Tax (EBT)
1 |
-51.79
|
-35.58
|
-52.3
|
-41.38
|
-38.83
|
-44.19
|
-64.9
|
-60.21
|
-66.64
|
-65.65
|
-61.06
|
-64.01
|
-68.06
|
-74.96
|
-83.27
|
Net income
1 |
-51.79
|
-35.58
|
-52.3
|
-41.38
|
-38.83
|
-44.19
|
-64.9
|
-60.21
|
-66.64
|
-65.65
|
-60.69
|
-63.91
|
-67.02
|
-74.96
|
-83.27
|
Net margin
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
EPS
2 |
-1.000
|
-0.6900
|
-1.010
|
-0.8000
|
-0.7400
|
-0.7800
|
-1.080
|
-0.9900
|
-1.090
|
-0.8100
|
-0.6940
|
-0.7117
|
-0.7081
|
-0.7750
|
-0.8450
|
Dividend per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
3/10/22
|
5/2/22
|
8/4/22
|
11/3/22
|
3/2/23
|
5/11/23
|
8/3/23
|
10/30/23
|
3/5/24
|
5/2/24
|
-
|
-
|
-
|
-
|
-
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net Debt
1 |
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Net Cash position
1 |
-
|
345
|
377
|
256
|
123
|
482
|
454
|
397
|
Leverage (Debt/EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Free Cash Flow
1 |
-
|
-47.7
|
-123
|
-157
|
-189
|
-236
|
-237
|
-216
|
ROE (net income / shareholders' equity)
|
-
|
-33.4%
|
-42%
|
-54.2%
|
-137%
|
-166%
|
-126%
|
-131%
|
ROA (Net income/ Total Assets)
|
-
|
-32.2%
|
-38.3%
|
-45.9%
|
-100%
|
-53.7%
|
-29.7%
|
-34.6%
|
Assets
1 |
-
|
184.9
|
389.5
|
366
|
235.7
|
478.5
|
976.4
|
807.7
|
Book Value Per Share
2 |
-
|
7.530
|
7.140
|
4.860
|
1.530
|
8.390
|
7.780
|
5.240
|
Cash Flow per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Capex
1 |
-
|
1.16
|
3.62
|
3.07
|
0.73
|
1.62
|
1.92
|
2.27
|
Capex / Sales
|
-
|
-
|
-
|
-
|
-
|
-
|
11.62%
|
3.93%
|
Announcement Date
|
8/25/20
|
3/4/21
|
3/10/22
|
3/2/23
|
3/5/24
|
-
|
-
|
-
|
Last Close Price
31.88
USD Average target price
45.9
USD Spread / Average Target +43.98% Consensus |
1st Jan change
|
Capi.
|
---|
| +139.70% | 3.16B | | +43.36% | 54.63B | | -5.31% | 39.92B | | +37.52% | 38.82B | | +14.75% | 26.86B | | -12.56% | 26.22B | | -22.45% | 18.78B | | +25.12% | 12.21B | | +0.04% | 12.16B | | +26.04% | 11.94B |
Other Biotechnology & Medical Research
|